Principles of protein folding, misfolding and aggregation

Seminars in Cell and Developmental Biology

Volumn 15, Issue 1, 2004, Pages 3-16

  Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amyloid formation; Biological self assembly; Energy landscape; Molecular evolution; Neurodegenerative disease

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA SYNUCLEIN; AMYLOID; BETA N ACETYLHEXOSAMINIDASE; CHAPERONE; CHAPERONIN; COLLAGEN; CRYSTALLIN; FIBRILLIN; HEAT SHOCK PROTEIN; HEMOGLOBIN; HUNTINGTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHENYLALANINE 4 MONOOXYGENASE; PREALBUMIN; PRION PROTEIN; PROCOLLAGEN; PROTEIN; PROTEIN P53; RHODOPSIN; TAU PROTEIN;

AGING; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BIOLOGY; CATARACT; CELL CYCLE; CELL ORGANELLE; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; CYSTIC FIBROSIS; CYTOPLASM; DISEASE ASSOCIATION; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; EVOLUTION; FAMILIAL AMYLOIDOSIS; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; MALIGNANT NEOPLASTIC DISEASE; MARFAN SYNDROME; MOLECULAR BIOLOGY; MOLECULE; MORPHOLOGY; MUTAGENESIS; NONHUMAN; OSTEOGENESIS IMPERFECTA; PARKINSON DISEASE; PHENYLKETONURIA; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RETINITIS PIGMENTOSA; RIBOSOME; SCURVY; SICKLE CELL ANEMIA; X RAY CRYSTALLOGRAPHY;

EID: 0842281551     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2003.12.008     Document Type: Conference Paper

References (103)

1. Branden C, Tooze J. Introduction to protein structure, 2nd ed. New York: Garland Publishing; 1999.
2. Ellis R.J., Minton A.P. Join the crowd. Nature. 425:2003;27-28.
3. Gething M.-J., Sambrook J. Protein folding in the cell. Nature. 355:1992;33-45.
4. Vendruscolo M., Zurdo J., MacPhee C.E., Dobson C.M. Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biological systems. Phil. Trans. R. Soc. Lond. A. 361:2003;1205-1222.
5. Karplus M. The Levinthal paradox, yesterday and today. Fold. Des. 2:1997;569-576.
6. Wolynes P.G., Onuchic J.N., Thirumalai D. Navigating the folding routes. Science. 267:1995;1619-1623.
7. Dill K.A., Chan H.S. From Levinthal to pathways to funnels. Nature Struct. Biol. 4:1997;10-19.
8. Dobson C.M., Sali A., Karplus M. Protein folding: a perspective from theory and experiment. Angew. Chem. Int. Ed. Eng. 37:1998;868-893.
9. Dinner A.R., Sali A., Smith L.J., Dobson C.M., Karplus M. Understanding protein folding via free energy surfaces from theory and experiment. Trends Biochem. Sci. 25:2000;331-339.
10. Baldwin R.L. Protein folding: matching speed and stability. Nature. 369:1994;183-184.
11. Jackson S.E. How do small single-domain proteins fold? Fold Des. 3:1998;R81-R91.
12. Matouschek A., Kellis J.T., Serrano L., Fersht A.R. Mapping the transition state and pathway of protein folding by protein engineering. Nature. 342:1989;122-126.
13. Fersht AR. Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding. New York: WH Freeman; 1999.
14. Fersht A.R. Transition-state structure as a unifying basis in protein-folding mechanisms: contact order, chain topology, stability, and the extended nucleus mechanism. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1525-1529.
15. Plaxco K., Dobson C.M. Time-resolved biophysical methods in the study of protein folding. Curr. Opin. Struct. Biol. 6:1996;630-636.
16. Dobson C.M., Karplus M. The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 9:1999;92-101.
17. Fersht A.R., Daggett V. Protein folding and unfolding at atomic resolution. Cell. 108:2002;573-582.
18. Vendruscolo M., Paci E., Dobson C.M., Karplus M. Three key residues form a critical contact network in a transition state for protein folding. Nature. 409:2001;641-646.
19. Makarov D.E., Plaxco K.W. The topomer search model: a simple, quantitative theory of two-state protein folding kinetics. Prot. Sci. 12:2003;17-26.
20. Davis R., Dobson C.M., Vendruscolo M. Determination of the structures of distinct transition state ensembles for a β-sheet peptide with parallel folding pathways. J. Chem. Phys. 117:2002;9510-9517.
21. Plaxco K.W., Simons K.T., Baker D. Contact order, transition state placement and the refolding rates of single domain proteins. J. Mol. Biol. 277:1998;985-994.
22. Baker D. A surprising simplicity to protein folding. Nature. 405:2000;39-42.
23. Capaldi A.P., Kleanthous C., Radford S.E. Im7 folding mechanism: misfolding on a path to the native state. Nature Struct. Biol. 9:2002;209-216.
24. Dobson CM. The nature and significance of protein folding. In: Pain RH, editor. Mechanisms of protein folding, 2nd ed. Oxford: Oxford University Press; 2000. p. 1-33.
25. Karplus M., Weaver D.L. Folding dynamics: the diffusion-collision model and experimental data. Prot. Sci. 3:1994;650-656.
26. Panchenko A.R., Luthey-Schulten Z., Wolynes P.G. Foldons, protein structural modules, and exons. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2008-2013.
27. Cheung M.S., Garcia A.E., Onuchic J.N. Protein folding mediated by solvation: water expulsion and formation of the hydrophobic core occur after the structural collapse. Proc. Natl. Acad. Sci. U.S.A. 99:2002;685-690.
28. Booth P.J., Curran A.R. Membrane protein folding. Curr. Opin. Struct. Biol. 9:1999;115-121.
29. Trieber D.K., Williamson J.R. Exploring the kinetic traps in RNA folding. Curr. Opin. Struct. Biol. 9:1999;339-345.
30. Hardesty B., Kramer G. Folding of a nascent peptide on the ribosome. Prog. Nucleic. Acid Res. Mol. Biol. 66:2001;41-66.
31. Yusupov M.M., Yusupova G.Z., Baucom A., Lieberman K., Earnest T.N., Cate J.H.et al. Crystal structure of the ribosome at 5.5 Å resolution. Science. 292:2001;883-896.
32. Jenni S., Ban N. The Chemistry of Protein Synthesis and Voyage Through the Ribosomal Tunnel. Curr. Op. Struct. Biol. 13:2003;212-219.
33. Gilbert RJC, Fucini P, Connell S, Fuller SD, Nierhaus KH, Robinson CV, Dobson CM, Stuart DL. Three-dimensional structures of translating ribosomes by cryo-EM, submitted for publication.
34. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 295:2002;1852-1858.
35. Hore P.J., Winder S.L., Roberts C.H., Dobson C.M. Stopped-flow photo-CIDNP observation of protein folding. J. Am. Chem. Soc. 119:1997;5049-5050.
36. Dobson C.M. Protein folding and disease: a view from the first Horizon symposium. Nature Rev. Drug Disc. 2:2003;154-160.
37. Ellis RJ, editor. The chaperonins. San Diego, CA: Academic Press; 1996.
38. Ellis R.J. Importance of the Anfinsen cage. Curr. Biol. 13:2003;R881-R883.
39. Pelham H.R. Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell. 46:1986;959-961.
40. Parsall D.A., Kowal A.S., Singer M.A., Lindquist S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature. 372:1994;475.
41. Hammon C., Helenius A. Quality control in the secretory pathway. Curr. Opin. Cell. Biol. 7:1995;523.
42. Kaufman R.J., Scheuner D., Schroder M., Shen X., Lee K., Liu C.Y., Arnold S.M. The unfolded protein response in nutrient sensing and differentiation. Nature Rev. Mol. Cell Biol. 3:2002;411-421.
43. Schubert U., Anton L.C., Gibbs J., Orbyry C.C., Yewdell J.W., Bennink J.R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:2000;770-774.
44. Matouschek A. Protein unfolding - an important process in vivo? Curr. Opin. Struct. Biol. 13:2001;98-104.
45. Radford S.E., Dobson C.M. From computer simulations to human disease: emerging themes in protein folding. Cell. 97:1999;291-298.
46. Thomas P.J., Qu B.H., Pedersen P.L. Defective protein folding as a basis of human disease. Trends Biochem. Sci. 20:1995;456-459.
47. Dobson C.M. The structural basis of protein folding and its links with human disease. Phil. Trans. R. Soc. Lond. B. 356:2001;133-145.
48. Tan S.Y., Pepys M.B. Amyloidosis. Histopathology. 25:1994;403-414.
49. Pepys MB. In: Weatherall DJ, Ledingham JG, Warrel DA, editors. The Oxford textbook of medicine, 3rd ed. Oxford: Oxford University Press; 1995. p. 1512-24.
50. Koo E.H., Lansbury P.T. Jr., Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9989-9990.
51. Dobson C.M. Getting out of shape - protein misfolding diseases. Nature. 418:2002;729-730.
52. Sunde M., Blake C.C.F. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Prot. Chem. 50:1997;123-159.
53. Jiménez J.L., Guijarro J.I., Orlova E., Zurdo J., Dobson C.M., Sunde M.et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18:1999;815-821.
54. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G.et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3590-3594.
55. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:1999;329-332.
56. Fändrich M., Fletcher M.A., Dobson C.M. Amyloid fibrils from muscle myoglobin. Nature. 410:2001;165-166.
57. Fändrich M., Dobson C.M. The behaviour of polyamino acids reveals an inverse side-chain effect in amyloid structure formation. EMBO J. 21:2002;5682-5690.
58. Lopez de la Paz M., Goldie K., Zurdo J., Lacrois E., Dobson C.M., Hoenger A.et al. De novo designed peptide-based amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16052-16057.
59. Krebs MRH, Morozova-Roche L, Daniel K, Robinson CV, Dobson CM. Observation of sequence specificity in the seeding of amyloid fibrils. Submitted for publication.
60. Serpell L.C., Blake C.C.F., Fraser P.E. Molecular structure of a fibrillar Alzheimer's Aβ fragment. Biochemistry. 39:2000;13269-13275.
61. Jiménez J.L., Nettleton E.J., Bouchard M., Robinson C.V., Dobson C.M., Saibil H.R. The protofilament structure of insulin amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 99:2002;9196-9201.
62. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F.et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16742-16747.
63. Wille H., Michelitsch M.D., Guenebaut V., Supattapone S., Serban A., Cohen F.E.et al. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci U.S.A. 99:1999;3563-3568.
64. Chamberlain A., MacPhee C.E., Zurdo J., Morozova-Roche L.A., Hill H.A.O., Dobson C.M.et al. Ultrastructural organisation of amyloid fibrils by atomic force microscopy. Biophys. J. 79:2000;3282-3293.
65. DuBay KF, Chiti F, Zurdo J, Dobson CM, Vendruscolo M. Predicting absolute amyloid aggregation rates of polypeptide chains. Submitted for publication.
66. Chiti F., Stefani M., Taddei N., Ramponi G., Dobson C.M. Rationalisation of mutational effects on peptide and protein aggregation rates. Nature. 424:2003;805-808.
67. Chiti F., Taddei N., Baroni F., Capanni C., Stefani M., Ramponi G.et al. Kinetic partitioning of protein folding and aggregation. Nature Struct. Biol. 9:2002;137-143.
68. Kelly J. Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8:1998;101-106.
69. Harper J.D., Lansbury P.T. Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66:1997;385-407.
70. Padrick S.B., Miranker A.D. "Islet amyloid" phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry. 41:2002;4694-4703.
71. Nettleton E.J., Tito P., Sunde M., Bouchard M., Dobson C.M., Robinson C.V. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys. J. 79:2000;1053-1065.
72. Caughey B., Lansbury P.T. Jr. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26:2003;267-298.
73. Schlunegger M.P., Bennett M.J., Eisenberg D. Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. Adv. Protein Chem. 50:1997;61-122.
74. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 100:2003;330-335.
75. Bouchard M., Zurdo J., Nettleton E.J., Dobson C.M., Robinson C.V. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9:2000;1960-1967.
76. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 418:2002;291.
77. Dobson CM. How do we explore the energy landscape for folding? In: Fraunfelder H, Deisenhofer J, Wolynes PG, editors. Simplicity and complexity in proteins and nucleic acids. Berlin: Dahlem University Press; 1999. p. 15-37.
78. Macario A.J.L., de Macario E.C. Sick chaperones and ageing: a perspective. Ageing Res. Rev. 1:2002;295-311.
79. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25:2000;95-98.
80. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
81. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteosome system by protein aggregation. Science. 292:2001;1552-1555.
82. Horwich A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J. Clin. Invest. 110:2002;1221-1232.
83. Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81:2003;678-699.
84. Ramirez-Alvarado M., Merkel J.S., Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8979-8984.
85. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., Fraser P.E.et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 385:1997;787-793.
86. Larsson G., Last A.M., Desmyter A., Decanniere K., Canet D., Spencer A. et al. A camelid antibody fragment inhibits amyloid fibril formation by human lysozyme. Nature. 424:2003;783-788.
87. Prusiner S. Prion diseases and the BSE crisis. Science. 278:1997;245-251.
88. Chien P., DePace A.H., Collins S.R., Weissman J.S. Generation of prion transmission barriers by mutational control of amyloid conformations. Nature. 424:2003;948-951.
89. Perutz M.F., Windle A.H. Cause of neuronal death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature. 412:2001;143-144.
90. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
91. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J. et al. Inherent cytotoxicity of aggregates implies a common origin for protein misfolding diseases. Nature. 416:2002;507-511.
92. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W.et al. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science. 300:2003;486-489.
93. Polverino de Laureto P, Taddei N, Frare E, Capanni C, Constantini S, Zurdo J. Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis. J Mol Biol 2003;334:14817-21.
94. Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., Hartl F.U. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 97:2000;7841-7846.
95. Csermely P. Chaperone overload is a possible contributor to 'civilization diseases'. Trends Genet. 17:2001;701-704.
96. Höppener J.W.M., Nieuwenhuis M.G., Vroom T.M., Ahrén B., Lips C.J.M. Role of Islet amyloid in Type 2 diabetes mellitus: consequence or cause? Mol. Cell. Endocrin. 197:2002;205-212.
97. Gejyo F., Homma N., Suzuki Y., Arakawa M. Serum levels of β2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N. Engl. J. Med. 314:1986;585-586.
98. Frausto da Silva JJR, Williams RJP. The biological chemistry of the elements. Oxford: Oxford University Press; 1991.
99. Schenck D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev. Neurosci. 3:2002;824-828.
100. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev. Neurosci. 4:2003;49-60.
101. Pepys M.B.et al. Targeted pharmocological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.
102. Hammarstrom P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 299:2003;713-716.
103. May B.C.et al. Potent inhibition of scrapie prion replication in cultured cells by bisacridines. Proc. Natl. Acad. Sci. U.S.A. 100:2003;3416-3421.